Metabolic reprogramming and cell fate regulation in alcoholic liver disease

Pancreatology

Volumn 15, Issue 4, 2015, Pages S61-S65

  Tsukamoto, Hidekazu ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hepatic stellate cells; Iron; M1 macrophage activation; MeCP2; Morphogens; Wnt

Indexed keywords

DELTA LIKE HOMOLOG 1 PROTEIN; MEMBRANE PROTEIN; MORPHOGEN; NECDIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ADIPOGENESIS; ALCOHOL LIVER DISEASE; CELL FATE; CELL REPROGRAMMING TECHNIQUE; CHRONIC INFLAMMATION; EPIGENETIC REPRESSION; HEPATIC STELLATE CELL; HUMAN; IRON METABOLISM; MACROPHAGE ACTIVATION; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; WNT SIGNALING; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ADIPOGENESIS; ANIMALS; HEPATIC STELLATE CELLS; HUMANS; LIVER DISEASES, ALCOHOLIC; MACROPHAGE ACTIVATION;

EID: 84924944125     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2015.03.003     Document Type: Review

References (40)

1. Uesugi, T., Froh, M., Arteel, G.E., Bradford, B.U., Thurman, R.G., Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 34 (2001), 101–108.
2. Lazaro, R., Wu, R., Lee, S., Zhu, N.L., Chen, C.L., French, S.W., et al. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology 61 (2014), 129–140.
3. Bonkovsky, H.L., Banner, B.F., Lambrecht, R.W., Rubin, R.B., Iron in liver diseases other than hemochromatosis. Semin Liver Dis 16 (1996), 65–82.
4. George, D.K., Goldwurm, S., MacDonald, G.A., Cowley, L.L., Walker, N.I., Ward, P.J., et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114 (1998), 311–318.
5. Uraz, S., Aygun, C., Sonsuz, A., Ozbay, G., Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. Dig Dis Sci 50 (2005), 964–969.
6. Valerio, L.G. Jr., Parks, T., Petersen, D.R., Alcohol mediates increases in hepatic and serum nonheme iron stores in a rat model for alcohol-induced liver injury. Alcohol Clin Exp Res 20 (1996), 1352–1361.
7. Otogawa, K., Kinoshita, K., Fujii, H., Sakabe, M., Shiga, R., Nakatani, K., et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 170 (2007), 967–980.
8. Yuan, X.M., Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis. Free Radic Res 30 (1999), 221–231.
9. Kennedy, J.I., Chandler, D.B., Jackson, R.M., Fulmer, J.D., Reduction in bleomycin-induced lung hydroxyproline content by an iron chelating agent. Chest 89 (1986), 123S–125S.
10. Graham, J.M., Paley, M.N., Grunewald, R.A., Hoggard, N., Griffiths, P.D., Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123:Pt 12 (2000), 2423–2431.
11. Honda, K., Casadesus, G., Petersen, R.B., Perry, G., Smith, M.A., Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 1012 (2004), 179–182.
12. Sumida, Y., Kanemasa, K., Fukumoto, K., Yoshida, N., Sakai, K., Nakashima, T., et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 36 (2006), 315–321.
13. Yano, M., Hayashi, H., Yoshioka, K., Kohgo, Y., Saito, H., Niitsu, Y., et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 39 (2004), 570–574.
14. Tsukamoto, H., Horne, W., Kamimura, S., Niemela, O., Parkkila, S., Yla-Herttuala, S., et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 96 (1995), 620–630.
15. Fletcher, L.M., Dixon, J.L., Purdie, D.M., Powell, L.W., Crawford, D.H., Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122 (2002), 281–289.
16. Lin, M., Rippe, R.A., Niemela, O., Brittenham, G., Tsukamoto, H., Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 272 (1997), G1355–G1364.
17. Tsukamoto, H., Lin, M., Ohata, M., Giulivi, C., French, S.W., Brittenham, G., Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol 277 (1999), G1240–G1250.
18. Xiong, S., She, H., Takeuchi, H., Han, B., Engelhardt, J.F., Barton, C.H., et al. Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem 278 (2003), 17646–17654.
19. Chen, L., Xiong, S., She, H., Lin, S.W., Wang, J., Tsukamoto, H., Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic macrophages. J Biol Chem 282 (2007), 5582–5588.
20. Xiong, S., She, H., Zhang, A.S., Wang, J., Mkrtchyan, H., Dynnyk, A., et al. Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 295 (2008), G512–G521.
21. Atkinson, P.G., Barton, C.H., High level expression of Nramp1G169 in RAW264.7 cell transfectants: analysis of intracellular iron transport. Immunology 96 (1999), 656–662.
22. Knutson, M.D., Vafa, M.R., Haile, D.J., Wessling-Resnick, M., Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood 102 (2003), 4191–4197.
23. Montosi, G., Paglia, P., Garuti, C., Guzman, C.A., Bastin, J.M., Colombo, M.P., et al. Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. Blood 96 (2000), 1125–1129.
24. Makui, H., Soares, R.J., Jiang, W., Constante, M., Santos, M.M., Contribution of Hfe expression in macrophages to the regulation of hepatic hepcidin levels and iron loading. Blood 106 (2005), 2189–2195.
25. Jiang, X., Baldwin, C.L., Iron augments macrophage-mediated killing of Brucella abortus alone and in conjunction with interferon-gamma. Cell Immunol 148 (1993), 397–407.
26. Asahina, K., Tsai, S.Y., Li, P., Ishii, M., Maxson, R.E. Jr., Sucov, H.M., et al. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 49 (2009), 998–1011.
27. Asahina, K., Zhou, B., Pu, W.T., Tsukamoto, H., Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology 53 (2011), 983–995.
28. Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H.F. Jr., Motomura, K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000), 35715–35722.
29. Hazra, S., Xiong, S., Wang, J., Rippe, R.A., Krishna, V., Chatterjee, K., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279 (2004), 11392–11401.
30. She, H., Xiong, S., Hazra, S., Tsukamoto, H., Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280 (2005), 4959–4967.
31. Yavrom, S., Chen, L., Xiong, S., Wang, J., Rippe, R.A., Tsukamoto, H., Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280 (2005), 40650–40659.
32. Tsukamoto, H., She, H., Hazra, S., Cheng, J., Miyahara, T., Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 21:Suppl. 3 (2006), S102–S105.
33. Cheng, J.H., She, H., Han, Y.P., Wang, J., Xiong, S., Asahina, K., et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 294 (2008), G39–G49.
34. Zhu, N.L., Wang, J., Tsukamoto, H., The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells. J Biol Chem 285 (2010), 30463–30471.
35. Zhu, N.L., Asahina, K., Wang, J., Ueno, A., Lazaro, R., Miyaoka, Y., et al. Hepatic stellate cell-derived delta-like homolog 1 (DLK1) in liver regeneration. J Biol Chem 287 (2012), 10355–10367.
36. Mann, J., Chu, D.C., Maxwell, A., Oakley, F., Zhu, N.L., Tsukamoto, H., et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138 (2010), 705–714.
37. Tsukamoto, H., Zhu, N.L., Wang, J., Asahina, K., Machida, K., Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol 27:Suppl. 2 (2012), 94–98.
38. Matsusue, K., Haluzik, M., Lambert, G., Yim, S.H., Gavrilova, O., Ward, J.M., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111 (2003), 737–747.
39. Medina-Gomez, G., Gray, S.L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet, 3, 2007, e64.
40. Hasenfuss, S.C., Bakiri, L., Thomsen, M.K., Williams, E.G., Auwerx, J., Wagner, E.F., Regulation of steatohepatitis and PPARgamma signaling by distinct AP-1 dimers. Cell Metab 19 (2014), 84–95.